Bluesight releases its 2024 Diversion Trends Report, a review of the impact of monitoring, preventing, and identifying controlled substance diversion in healthcare settings. Examining data across controlled substance transactions from January 2022 through December 2023, the report aims to provide healthcare providers with critical insights to drive operational improvements and enhance patient safety. Key findings in the report include that waste events, which can be a risk factor for diversion, added up to over 16 million wasted packages or approximately $38 million in lost costs; and fentanyl is the top drug associated with variances, followed by midazolam and hydromorphone. Further, the report found that diversion monitoring efforts are improving, with fewer discrepant transactions and more efficient investigations. At the beginning of 2022, investigations took an average of 84 days to close. As of December 2023, they took an average of 47 days.